Literature DB >> 23866896

Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae.

Christine J Ko, Jennifer M McNiff, Angelika Iftner, Thomas Iftner, Jennifer Nam Choi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23866896     DOI： 10.1016/j.jaad.2012.03.027

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.

Authors:  Daniel N Cohen; Steven K Lawson; Aaron C Shaver; Liping Du; Harrison P Nguyen; Qin He; Douglas B Johnson; Wilfred A Lumbang; Brent R Moody; James L Prescott; Pranil K Chandra; Alan S Boyd; Jeffrey P Zwerner; Jason B Robbins; Stephen K Tyring; Peter L Rady; James D Chappell; Yu Shyr; Jeffrey R Infante; Jeffrey A Sosman
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

Review 2.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869

3.  Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection.

Authors:  Eric Frouin; Bernard Guillot; Marion Larrieux; Ariane Tempier; Nathalie Boulle; Vincent Foulongne; Céline Girard; Valérie Costes; Jérome Solassol
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

4.  The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.

Authors:  Karin J Purdie; Charlotte M Proby; Hasan Rizvi; Heather Griffin; John Doorbar; Mary Sommerlad; Mariet C Feltkamp; Els Van der Meijden; Gareth J Inman; Andrew P South; Irene M Leigh; Catherine A Harwood
Journal:  Front Microbiol       Date:  2018-08-14       Impact factor: 5.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.